Overview / Abstract: |
Target Audience This educational activity is directed toward hematologists and hematologist-oncologists who treat patients with cold agglutinin disease. Fellows, nurses, nurse practitioners, and other health care professionals interested in the management of patients with cold agglutinin disease are also invited to participate. Activity Overview Cold agglutinin disease (CAD) has a significant impact on patients’ quality of life. Historically, the limited availability of treatment options has hindered management of CAD. However, the treatment landscape is shifting as novel therapies are developed based on improved understanding of the role of the complement system in the pathogenesis of CAD. Health care professionals require a strong foundation of knowledge in the efficacy, safety, and role of both available and emerging therapies for CAD to improve the outcomes in this patient population. This program features experts presenting important topics on CAD, including the burden of disease and the impact of CAD on patient quality of life, as well as the role of the complement system in CAD. The program also includes expert review of current and emerging data surrounding strategies for rapid and accurate diagnosis, current management approaches and the potential of emerging treatments. This educational activity is an archive of the live virtual presentation held on June 10, 2021. Learning Objectives Upon successful completion of this activity, you should be better prepared to: Describe the clinical burden of cold agglutinin disease. |
Expiration |
Jul 14, 2022 |
Discipline(s) |
Physician CME |
Format |
Online |
Credits / Hours |
1.5 AMA PRA Category 1 Credit(s)™ |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Faculty FACULTY_NAME FACULTY_NAME FACULTY_NAME FACULTY_NAME |
Sponsors / Supporters / Grant Providers |
Sanofi Genzyme |
Keywords / Search Terms |
Relias LLC Relias LLC., FreeCME., Agglutinin Disease Free CE CME |